Per-target agreement enables Ascidian to pursue additional internal and collaborative programs within neurology and other therapeutic areasCollaboration and Licensing Agreement • June 10th, 2024
Contract Type FiledJune 10th, 2024Ascidian’s RNA exon editing platform is designed to advance the therapeutic possibilities of RNA medicine and treat diseases not addressed by today’s gene editing technologies. The company designs and develops RNA exon editing therapeutics that edit RNA exons at the kilobase scale.